Figure 1
Figure 1. Kaplan-Meier curves for overall, leukemia-free, and event-free survival comparisons. (A) Overall survival in mutated () and unmutated (—) MDS patients (n = 88, log-rank test, P = .005), (B) freedom from AML progression in mutated () and unmutated (—) MDS patients (n = 88, log-rank test; P = .035), and (C) event of death or AML transformation-free survival in mutated () and unmutated (—) MDS patients (n = 88, log-rank test, P = .032).

Kaplan-Meier curves for overall, leukemia-free, and event-free survival comparisons. (A) Overall survival in mutated () and unmutated (—) MDS patients (n = 88, log-rank test, P = .005), (B) freedom from AML progression in mutated () and unmutated (—) MDS patients (n = 88, log-rank test; P = .035), and (C) event of death or AML transformation-free survival in mutated () and unmutated (—) MDS patients (n = 88, log-rank test, P = .032).

Close Modal

or Create an Account

Close Modal
Close Modal